Dawson reports a relationship with D&D Pharmatech that includes: equity or stocks
GLP-1 slows intestinal transit, making dehydration a major risk factor for constipation
In addition to the benefits of these injections, it is crucial to account for lifestyle modifications
Among those agents are the oldest non-insulin glucose-lowering drugs, the drug class known as sulfonylureas (SUs)
Circulating levels of active GLP-1 were increased approximately 4-fold in response to 10 mg/kg sitagliptin (Figure 1C)
Mounjaro's website states the most common side effects of the drug include, "nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach (abdominal) pain." Similarly, Ozempic's website states the most common side effects of the drug may include, "nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation." Novo Nordisk, the maker of Ozempic, told ABC News in a statement that "gastrointestinal events are well-known side effects," adding the majority are "mild to moderate" and typically only occur for a "short duration" of time